Shares of Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report) traded down 6.1% on Tuesday . The stock traded as low as $1.69 and last traded at $1.69. 1,903 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 5,564 shares. The stock had previously closed at $1.80.
Kiromic BioPharma Stock Performance
The stock’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $2.39. The company has a market capitalization of $2.61 million, a PE ratio of -0.17 and a beta of 1.97.
Kiromic BioPharma (NASDAQ:KRBP – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported ($0.74) earnings per share for the quarter.
About Kiromic BioPharma
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Featured Articles
- Five stocks we like better than Kiromic BioPharma
- How to Evaluate a Stock Before Buying
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What Does a Stock Split Mean?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Investors Need to Know About Upcoming IPOs
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
